MAP2K7 and colorectal cancer: MEK inhibitors have also shown promise in preclinical studies of KRAS/NRAS/BRAF mutant colorectal cancer, but early phase clinical trials with the MEK inhibitor selumetinib (AZD6244 hydrogen sulfate) failed to demonstrate significant improvement in progression-free survival [9, 10].